CRL — Charles River Laboratories International, Inc. stock price, charts and financials

QT71Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. (NYSE: CRL) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
234.12
+3.25+1.41%
CRLQT71Charles River Laboratories International, Inc.·NYSE
234.12+1.41%
Earnings
Up 1.4% — Reported earnings — EPS beat by 6%, revenue beat by 2%.
High confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E-EPS (ttm)-3.76Insider Own1.50%Shs Outstand48.17MPerf Week-2.62%
Market Cap11.28BForward P/E18.96EPS next Y12.35Insider Trans-10.35%Shs Float47.62MPerf Month1.16%
Enterprise Value14.14BPEG-EPS next Q-Inst Own-Short Float7.02%Perf Quarter35.86%
Income-186.00MP/S2.80EPS this Y395.35%Inst Trans-Short Ratio3.80Perf Half Y9.80%
Sales4.03BP/B3.77EPS next Y11.19%ROA-2.39%Short Interest3.34MPerf YTD17.37%
Book/sh62.03P/C58.73EPS next 5Y8.31%ROE-5.74%52W High242.74 -3.55%Perf Year40.27%
Cash/sh3.99P/FCF28.62EPS past 3/5Y-ROIC7.14%52W Low144.26 62.29%Perf 3Y11.23%
Dividend Est.-EV/EBITDA48.59Sales past 3/5Y0.33% 6.55%Gross Margin31.86%Volatility3.39% 3.63%Perf 5Y-40.39%
Dividend TTM-EV/Sales3.51EPS Y/Y TTM-1980.00%Oper. Margin11.77%ATR (14)8.91Perf 10Y171.13%
Dividend Ex-Date-Quick Ratio1.03Sales Y/Y TTM-0.57%Profit Margin-4.59%RSI (14)60.51Recom2.27
Dividend Gr. 3/5Y-Current Ratio1.36EPS Q/Q-11.97%SMA202.26%Beta1.35Target Price230.78
Payout0.00%Debt/Eq0.95Sales Q/Q1.22%SMA5012.82%Rel Volume1.27Prev Close230.87
Employees19,700LT Debt/Eq0.94EarningsAug 05SMA20024.64%Avg Volume901.35KPrice234.12
IPO DateJun 23, 2000Option/ShortYes / YesEPS/Sales Surpr.5.99% 1.88%Net Debt/EBITDA9.86Volume1,146,545Change1.41%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-20-26DowngradeCLSAOutperformHold
Jul-13-26ReiteratedMizuhoNeutral$192$230
Jul-09-26ReiteratedMorgan StanleyOverweight$220$260
Jul-01-26ReiteratedBernstein$250
Jul-01-26ReiteratedBNP Paribas$250
Jun-17-26UpgradeMorgan StanleyEqual WeightOverweight$185$220
May-29-26UpgradeCLSAHoldOutperform$219
May-08-26ReiteratedRobert W. Baird$200$213
May-08-26ReiteratedMizuho SecuritiesNeutral$175$192
May-08-26ReiteratedBarclaysOverweight$210$220
Latest News
Aug-04-26
Aug-01-26
Jul-30-26
Jul-29-26
Jul-27-26
Jul-23-26
Jul-22-26
Jul-21-26
Jul-17-26
Jul-15-26
Jul-14-26
Jul-13-26
Jul-07-26
Company

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/27/2025
FY 2024
12/28/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,0274,0154,0504,1293,9763,5402,9242,6212,266
Cost of Goods Sold Incl. D&A2,7442,7902,7182,6272,5132,2061,8501,6631,426
Gross Profit1,2831,2261,3321,5031,4631,3351,074958840
Selling, General and Administrative Excl. Other717743751748665620529518444
Research and Development
000000000
Other Operating Expense92-253531371471251128965
Operating Income474508227617651590433351331
Interest Expense1061071261375974866164
Unusual Expense
Non-Operating Income (Expense)-534-500-810131-351011414
Net Income Before Taxes-166-10093581623481447304282
Income Taxes18436810113082825054
Consolidated Net Income-186-14410475486391364252226
Net Income From Continuing Operations-182-14225480493399365254227
Net Income-186-14410475486391364252226
EPS (Recurring)-3.75-2.910.209.279.577.777.355.174.72
EPS (Basic, Before Extraordinaries)-3.75-2.910.209.279.577.777.355.174.72
EPS (Diluted)-3.76-2.910.209.229.487.607.205.074.62
EBITDA2914115811,032986820768563507
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio930.8025.6422.9949.5834.7030.1324.50
Price To Sales Ratio2.852.542.342.922.795.324.272.862.40
Gross Margin31.8630.5432.8936.4036.8037.7136.7336.5537.07
Operating Margin11.7712.655.6014.9416.3716.6714.8113.3914.61
Net Margin-4.62-3.590.2511.5012.2211.0512.459.619.97
Shares Outstanding495051515150504948
Market Capitalization11,47210,1839,49412,05611,11318,83912,4937,4855,433
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$256.24$221.99$187.73$153.48$119.23 Close Price0.00M4.22M8.44M12.66M16.88MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FOSTER JAMES CDirectorJun 29 '26Sale225.0075,00016,875,00031,596Jul 01
LaPlume Joseph WEVP, Corp Strategy & DevelopMar 03 '26Buy174.54254,36427,448Mar 04
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 22 '25Sale163.7240065,48823,716Jan 20
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 18 '25Sale157.60800126,08024,116Aug 20
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 07 '25Sale150.0440060,01624,916Aug 08
MASSARO GEORGEDirectorMay 15 '25Sale137.5714019,2605,575May 16
MASSARO GEORGEDirectorMay 14 '25Sale140.7414019,7025,715May 15
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 13 '25Sale145.4150072,70519,513May 15
FOSTER JAMES CChairman, President and CEOFeb 20 '25Buy165.016,0751,002,436183,639Feb 21
Girshick BirgitCorporate Executive VP & COOFeb 20 '25Buy164.631,514249,25055,058Feb 21
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 20 '25Sale162.504,400715,00020,013Feb 21
WALLMAN RICHARD FDirectorNov 07 '24Sale216.177,6211,647,4180Nov 12
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 08 '24Sale199.361,780354,86122,521Aug 12
FOSTER JAMES CChairman, President and CEOAug 01 '24Sale250.0025,0006,250,000188,251Aug 05
Knell Michael GunnarCSVP&Chief Accounting OfficerMar 08 '24Sale267.521,616432,3127,024May 29
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.